4 Health Services Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 55 points (-0.4%) at 14,948 as of Wednesday, Aug. 21, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 846 issues advancing vs. 2,101 declining with 78 unchanged.

The Health Services industry currently sits down 0.3% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Mindray Medical International ( MR), down 1.7%, Universal Health Services ( UHS), down 1.6%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.2%, Smith & Nephew ( SNN), down 1.1% and St Jude Medical ( STJ), down 1.0%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry higher today. As of noon trading, WuXi PharmaTech (Cayman is up $0.77 (3.2%) to $24.86 on average volume. Thus far, 230,183 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 326,300 shares. The stock has ranged in price between $24.00-$25.00 after having opened the day at $24.12 as compared to the previous trading day's close of $24.09.

Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $1.7 billion and is part of the health care sector. Shares are up 53.0% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full WuXi PharmaTech (Cayman Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Grifols ( GRFS) is up $0.30 (1.0%) to $31.48 on light volume. Thus far, 47,172 shares of Grifols exchanged hands as compared to its average daily volume of 435,000 shares. The stock has ranged in price between $30.89-$31.70 after having opened the day at $31.16 as compared to the previous trading day's close of $31.18.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $10.8 billion and is part of the health care sector. Shares are up 21.1% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Edwards Life ( EW) is up $0.98 (1.4%) to $71.44 on average volume. Thus far, 576,544 shares of Edwards Life exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $70.60-$72.61 after having opened the day at $70.60 as compared to the previous trading day's close of $70.46.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $7.8 billion and is part of the health care sector. Shares are down 21.9% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Edwards Life a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Edwards Life Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Intuitive Surgical ( ISRG) is up $2.71 (0.7%) to $388.16 on light volume. Thus far, 76,702 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 581,500 shares. The stock has ranged in price between $383.50-$388.49 after having opened the day at $385.11 as compared to the previous trading day's close of $385.45.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $15.3 billion and is part of the health care sector. Shares are down 21.5% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Intuitive Surgical a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio